Insulin Drug Interactions

Drugs That Increase Hypoglycemic Effect (Potentiate Insulin)

Drugs That Decrease Insulin Effect (Cause Hyperglycemia / Antagonize)

Drugs That Mask Hypoglycemia Symptoms

Physicochemical / Pharmacokinetic Interactions

• Certain insulin preparations must not be mixed: glargine (Lantus) and detemir are incompatible with other insulins due to altered pH (glargine is formulated at pH 4), which would alter the pharmacokinetics of any co-mixed insulin — Katzung's Basic and Clinical Pharmacology, 16th Ed.
• Regular insulin + NPH: compatible and can be mixed; the ratio affects the combined pharmacokinetic profile.
• Protamine-containing insulins (NPH): risk of hypersensitivity in patients with protamine allergy (e.g., prior protamine sulfate exposure during cardiac procedures).

Key Clinical Points

1. β-blockers are the most clinically dangerous interaction — they both prolong hypoglycemia and mask its adrenergic warning signs. If a β-blocker is required, prefer cardioselective ones (metoprolol, atenolol), which have a lesser but not absent effect.
2. Glucocorticoids are the most common cause of insulin resistance in hospitalized patients; insulin doses often need to be substantially increased.
3. Alcohol is particularly dangerous in type 1 diabetics — it prevents gluconeogenic recovery from hypoglycemia and the impaired sensorium may prevent the patient from recognizing it.
4. ACE inhibitors may genuinely improve insulin sensitivity (beneficial) but require monitoring for hypoglycemia.
5. CKD prolongs insulin half-life (reduced renal degradation), effectively increasing insulin effect and hypoglycemia risk independently of any drug interaction — Brenner and Rector's The Kidney.

Metformin — Mechanism of Action

1. Primary Target: Inhibition of Mitochondrial Complex I

• Reduces ATP production → raises the AMP:ATP ratio intracellularly
• High AMP:ATP ratio acts as a cellular "energy stress" signal

2. Activation of AMPK (AMP-Activated Protein Kinase)

• Phosphorylates TORC2 (transducer of regulated CREB activity 2), sequestering it in the cytoplasm
• Without nuclear TORC2, the transcription factor CREB cannot drive expression of PGC-1α (peroxisome proliferator-activated receptor-γ coactivator 1α)
• Without PGC-1α, transcription of key gluconeogenic enzymes — glucose-6-phosphatase and PEPCK (phosphoenolpyruvate carboxykinase) — is suppressed

3. Net Metabolic Effects

4. Key Clinical Implications of the Mechanism

• No insulin secretion stimulated → metformin alone carries minimal hypoglycemia risk (does not depend on functional β-cells)
• Reduces fasting glucose preferentially (hepatic gluconeogenesis is the dominant source of fasting hyperglycemia in T2DM)
• Lactic acidosis risk: mitochondrial respiratory chain inhibition impairs oxidative metabolism and hepatic lactate clearance; risk is markedly amplified in renal impairment (metformin accumulates) and tissue hypoxia
• Cardiovascular benefit (UKPDS): likely partly attributable to lipid-lowering effects via AMPK-mediated inhibition of lipogenesis

Metformin — Side Effects

1. Gastrointestinal (Most Common — 10–25%)

• Nausea, vomiting
• Abdominal cramps, bloating, indigestion
• Diarrhea (most troublesome; leads to discontinuation in 3–5% of patients)
• Anorexia / reduced appetite (can be exploited therapeutically — contributes to mild weight loss)

• Start at a low dose (500 mg daily) and titrate gradually over weeks
• Take with meals
• Extended-release (XR) formulation has significantly fewer GI effects and can substitute for immediate-release in intolerant patients

2. Lactic Acidosis (Rare but Potentially Fatal)

• Incidence: ~0.05 cases per 1,000 patient-years — rare in therapeutic use
• Definition (MALA — metformin-associated lactic acidosis): arterial pH ≤ 7.35 + lactate > 5 mmol/L (45 mg/dL)

3. Vitamin B₁₂ Deficiency (Long-Term Use)

• Long-term metformin use is associated with 20–30% lower serum B₁₂ levels
• Mechanism: metformin interferes with the calcium-dependent absorption of the vitamin B₁₂–intrinsic factor complex in the terminal ileum
• Clinically significant in patients with:
  • Peripheral neuropathy (can worsen or be confused with diabetic neuropathy)
  • Macrocytic anemia
• Increased calcium intake may partially prevent B₁₂ malabsorption
• Monitoring: periodic B₁₂ levels recommended, especially with long-term use or neurological symptoms

4. No Hypoglycemia (When Used as Monotherapy)

• Metformin does not stimulate insulin secretion → no risk of hypoglycemia alone
• Hypoglycemia can occur when combined with insulin or insulin secretagogues (sulfonylureas, meglitinides) — dose adjustment may be needed

5. No Weight Gain

• Unlike sulfonylureas or insulin, metformin is weight-neutral or causes mild weight loss (via appetite suppression)

Summary Table

Metformin — Drug Interactions

1. Pharmacokinetic Interactions — Renal Transporter Competition (OCT2 / MATE)

• Uptake into renal tubular cells: organic cation transporter 2 (OCT2) and OCT1
• Export into urine: multidrug and toxin extrusion proteins (MATE1/2)

OCT2 genetic polymorphisms (SNPs) also alter metformin pharmacokinetics interindividually. — Brenner and Rector's The Kidney

2. Iodinated Contrast Media (Procedural Interaction)

• IV contrast can cause contrast-induced nephropathy (CIN) → acute kidney injury → metformin accumulates → lactic acidosis risk

3. Pharmacodynamic Interactions — Enhanced Lactic Acidosis Risk

4. Pharmacodynamic Interactions — Enhanced Hypoglycemia Risk

5. Other Notable Interactions

Summary of Key Interactions

Aspirin (Acetylsalicylic Acid) — Side Effects

1. Gastrointestinal (Most Common)

2. Bleeding / Antiplatelet Effect

• Aspirin irreversibly acetylates platelet COX-1 → permanently blocks thromboxane A₂ synthesis for the platelet's lifespan (~10 days)
• Effect: impaired primary hemostasis (↑ bleeding time)
• Clinically relevant in:
  • Surgery (hold aspirin ≥7 days pre-op if not for cardiac indication)
  • Combined with anticoagulants (warfarin, heparins, DOACs) → significantly ↑ bleeding risk
  • Spontaneous petechiae / purpura at high doses (salicylism)

3. Hypersensitivity / Aspirin-Exacerbated Respiratory Disease (AERD)

• Prevalence: ~0.3% of the general population; up to 10–20% of asthmatics, especially with nasal polyps or chronic rhinitis
• Mechanism: COX-1 inhibition diverts arachidonic acid toward the lipoxygenase pathway → ↑ leukotrienes (LTC₄, LTD₄) → bronchoconstriction, rhinorrhoea, urticaria
• Samter's triad: asthma + nasal polyps + aspirin sensitivity
• Manifestations: bronchospasm, urticaria/angioedema, rhinorrhoea, anaphylactoid reactions
• Cross-reactivity with other NSAIDs (COX-1 inhibitors) is common

4. Salicylism (Chronic Toxicity)

5. Acute Overdose — Salicylate Poisoning

1. Early: direct medullary stimulation → respiratory alkalosis (hyperventilation, ↓ PaCO₂)
2. Later: uncoupling of oxidative phosphorylation + inhibition of Krebs cycle → high anion gap metabolic acidosis (↑ lactate, pyruvate, ketones)
3. In children: metabolic acidosis predominates

6. Renal Effects

• Acute: reduced renal prostaglandins (PGE₂, PGI₂) → ↓ renal blood flow → acute kidney injury (especially in volume-depleted, elderly, CKD, or heart failure patients)
• Chronic: analgesic nephropathy — tubulointerstitial nephritis with renal papillary necrosis from long-term combined analgesic use (aspirin + phenacetin/acetaminophen) — Robbins & Kumar Basic Pathology
• Salicylate clearance is reduced in CKD → drug accumulation

7. Hepatotoxicity

• Dose-dependent hepatotoxicity occurs especially at high anti-inflammatory doses
• Liver histology: nonspecific focal hepatitis, hepatocellular degeneration, hydropic changes (no steatosis — distinguishes it from Reye syndrome)
• Reversible on drug withdrawal — Sleisenger & Fordtran's GI and Liver Disease

8. Reye Syndrome (Paediatric — Special Risk)

• Rare but potentially fatal syndrome: encephalopathy + fatty degeneration of the liver
• Linked to aspirin use in children/teenagers with viral illnesses (influenza, varicella)
• Aspirin is contraindicated in children < 16 years with febrile illness for this reason
• Mechanism: mitochondrial dysfunction; not simply drug-induced liver disease

9. Uric Acid / Gout Effects (Dose-Dependent, Paradoxical)

• Low doses (<2 g/day): inhibit uric acid secretion → ↑ serum urate → can precipitate or worsen gout
• High doses (>4 g/day): inhibit uric acid reabsorption → uricosuric effect → ↓ serum urate
• Intermediate doses have unpredictable effects

10. Other Effects

Summary by Dose

Definitions: Heavy Menstrual Bleeding — Cyclical, Acyclical, Regular, Irregular

Foundational Framework — FIGO Terminology

Core Definitions

Heavy Menstrual Bleeding (HMB)

Excessive menstrual bleeding that interferes with a woman's physical, emotional, social, and quality of life. The definition is menstrual bleeding deemed excessive by the patient, regardless of duration, frequency, or timing.

• Previously called menorrhagia (now a discarded term)
• The older quantitative threshold of >80 mL per cycle has been retained in some texts (e.g., Berek & Novak's Gynecology) but is clinically impractical to measure; patient-reported impact is now the primary criterion
• Bleeding must be present for ≥6 months to qualify as chronic abnormal uterine bleeding

Regular Menstrual Bleeding

Irregular Menstrual Bleeding

Unpredictable onset of menses, with cycle variations >20 days over a period of 1 year.

• Reflects loss of the normal hormonal rhythm, most commonly due to anovulation
• Common in polycystic ovary syndrome (PCOS), perimenopause, thyroid disorders, hyperprolactinaemia

Cyclical Heavy Menstrual Bleeding

• Corresponds to heavy bleeding at the time of menstruation
• Typically associated with ovulatory causes: structural lesions (fibroids, polyps, adenomyosis), coagulopathies, endometrial causes, or primary HMB
• The bleeding pattern is cyclical because it follows the endometrial shedding rhythm driven by ovarian hormones

Acyclical Heavy Menstrual Bleeding

• Also called intermenstrual bleeding in FIGO terminology: "bleeding episodes between normally timed menstrual periods"
• Raises concern for structural or malignant pathology: endometrial polyps, submucosal fibroids, endometrial hyperplasia, endometrial carcinoma, cervical pathology, or infection
• Anovulatory bleeding can also appear acyclical due to fluctuating, unpredictable oestrogen levels

How the Terms Relate

Clinical Significance

• Cyclical HMB (regular) → think structural causes (PALM: Polyp, Adenomyosis, Leiomyoma, Malignancy/hyperplasia) or non-structural (COEIN: Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified) — the PALM-COEIN classification (FIGO 2011)
• Acyclical/irregular HMB → always warrants investigation to exclude endometrial malignancy, especially in women ≥40 or with risk factors; anovulatory bleeding must also be excluded
• Anovulatory cycles may be regular in timing but more often are irregular, presenting as prolonged amenorrhoea followed by episodes of heavy bleeding due to fluctuating oestrogen without progesterone opposition — Tintinalli's Emergency Medicine

Definitions: Superficial and Deep Dyspareunia

Dyspareunia (General)

Complaint of persistent or recurrent pain or discomfort associated with attempted or complete vaginal penetration. — Campbell Walsh Wein Urology, 3-Volume Set (ICS/ICSM terminology, Haylen et al., 2010)

• Pain due to lack of vaginal lubrication (vaginal dryness)
• Vaginismus — recurrent or persistent spasm of the vaginal musculature that interferes with vaginal penetration (though these can coexist)

Superficial (Introital) Dyspareunia

Complaint of pain or discomfort on vaginal entry or at the vaginal introitus.

• Also called entry dyspareunia or introital dyspareunia
• Pain is felt at or near the vaginal opening at the moment of attempted or initial penetration
• Anatomical zone: the vulva, vestibule, hymen, and vaginal introitus

Deep Dyspareunia

Complaint of pain or discomfort on deeper penetration (mid- or upper vagina).

• Pain is felt inside the pelvis during or after deep thrusting
• Anatomical zone: mid-vagina to supracervical / posterior fornix region
• Often described as a deep aching, pressure, or "hitting" sensation

Additional Related Subtypes (ICS Classification)

Clinical Distinction Summary